Prasugrel (BioDeep_00000033357)
human metabolite blood metabolite
代谢物信息卡片
5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetic acid
化学式: C20H20FNO3S (373.1147862)
中文名称: 普拉格雷
谱图信息:
最多检出来源 Homo sapiens(blood) 40%
分子结构信息
SMILES: CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1
InChI: InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3
描述信息
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thereby inhibiting ADP-mediated platelet activation and aggregation. Prasugrel inhibits ADP-mediated platelet aggregation more rapidly, more consistently and to a greater extent (at least 30\\\%) than clopidogrel. The increased potency of prasugrel appears to be due to more efficient conversion to its active metabolite. The relationship, however, between increased platelet aggregation and clinical response has not been determined. Prasugrel carries a higher risk of bleed compared to clopidogrel, which may be a result of its higher potency. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI).
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
同义名列表
12 个代谢物同义名
5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetic acid; 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4H,5H,6H,7H-thieno[3,2-c]pyridin-2-yl acetate; Hydrochloride, prasugrel; Prasugrel hydrochloride; HCL, Prasugrel; Prasugrel HCL; Prasugrel; 747, CS; Effient; Efient; CS-747; PCR 4099
数据库引用编号
10 个数据库交叉引用编号
- ChEBI: CHEBI:87715
- ChEBI: CHEBI:87723
- PubChem: 6918456
- HMDB: HMDB0015625
- DrugBank: DB06209
- ChEMBL: CHEMBL1201772
- MeSH: Prasugrel Hydrochloride
- chemspider: 5293653
- CAS: 150322-43-3
- medchemexpress: HY-15284
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Gjin Ndrepepa, Shqipdona Lahu, Alp Aytekin, Maria Scalamogna, John Joseph Coughlan, Senta Gewalt, Costanza Pellegrini, Katharina Mayer, Adnan Kastrati. One-Year Ischemic and Bleeding Events According to Renal Function in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Third-Generation Antiplatelet Drugs.
The American journal of cardiology.
2022 08; 176(?):15-23. doi:
10.1016/j.amjcard.2022.04.040. [PMID: 35606172] - Carol Anne Graham, Mary K Tan, Derek P Chew, Christopher P Gale, Keith A A Fox, Akshay Bagai, Mark A Henderson, Ata Ur Rehman Quraishi, Jean-Pierre Déry, Asim N Cheema, Harold Fisher, David Brieger, Sohrab R Lutchmedial, Shahar Lavi, Brian Y L Wong, Tomas Cieza, Shamir R Mehta, Neil Brass, Shaun G Goodman, Andrew T Yan. Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT).
Heart and vessels.
2022 Aug; 37(8):1291-1298. doi:
10.1007/s00380-022-02029-8. [PMID: 35089380] - Yuichi Saito, Takeshi Nishi, Shinichi Wakabayashi, Yuji Ohno, Hideki Kitahara, Noritaka Ariyoshi, Yoshio Kobayashi. Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel.
Journal of atherosclerosis and thrombosis.
2022 Jul; 29(7):1031-1039. doi:
10.5551/jat.63035. [PMID: 34234079] - Nishank Jain, Milind A Phadnis, Bradley C Martin, Jawahar L Mehta. Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis.
The American journal of cardiology.
2022 01; 162(?):209-211. doi:
10.1016/j.amjcard.2021.10.001. [PMID: 34740395] - Chih-Chin Shih, Melissa V Chan, Nicholas S Kirkby, Ivana Vojnovic, Jane A Mitchell, Paul C Armstrong, Timothy D Warner. Platelet inhibition by P2Y12 antagonists is potentiated by adenosine signalling activators.
British journal of pharmacology.
2021 12; 178(23):4758-4771. doi:
10.1111/bph.15659. [PMID: 34383973] - Immaneni Sathyamurthy, M S Hiremath, Jitendra Pal Sawhney, Subhash Chandra, Hrudanand Mishra, C K Ponde, Shuvanan Ray, Suhas Hardas, Sunil Sathe, P C Rath, Bagirath R, Girish B Navasundi, Vilas Magarkar, C N Makhale, Suvro Banerjee, P R Vaidyanathan, Amal Kanti Sen, Pandey Bp, Swami Onkar C. Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor.
The Journal of the Association of Physicians of India.
2021 Oct; 69(10):11-12. doi:
NULL. [PMID: 34781659] - Asmaa A Gomaa, Hanan S El-Abhar, Dalaal M Abdallah, Azza S Awad, Ayman A Soubh. Prasugrel anti-ischemic effect in rats: Modulation of hippocampal SUMO2/3-IкBα/Ubc9 and SIRT-1/miR-22 trajectories.
Toxicology and applied pharmacology.
2021 09; 426(?):115635. doi:
10.1016/j.taap.2021.115635. [PMID: 34174262] - Thomas A Mavrakanas, Omer Kamal, David M Charytan. Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure.
Clinical journal of the American Society of Nephrology : CJASN.
2021 05; 16(5):757-764. doi:
10.2215/cjn.12120720. [PMID: 33811128] - Mohammed A Abosheasha, Afnan H El-Gowily. Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach.
Drug development research.
2021 04; 82(2):217-229. doi:
10.1002/ddr.21743. [PMID: 32984987] - Taiki Masuyama, Masashi Sakuma, Ryutaro Waku, Suguru Hirose, Keijiro Kitahara, Jin Naganuma, Hiroko Yazawa, Shigeru Toyoda, Shichiro Abe, Toshiaki Nakajima, Teruo Inoue. Effects of switching from clopidogrel to prasugrel at the chronic phase after coronary stenting on antiplatelet action and vascular endothelial function: Switch-Pras study.
Heart and vessels.
2021 Apr; 36(4):442-451. doi:
10.1007/s00380-020-01714-w. [PMID: 33113567] - Masato Nakamura, Yoshihiro Morino, Tsunekazu Kakuta, Yoshiki Hata, Itaru Takamisawa, Kengo Tanabe, Hitoshi Anzai, Akihiko Takahashi, Kazushige Kadota, Hiroshi Suzuki, Tetsuzo Wakatsuki, Hideki Okayama, Jun Yamashita, Takashi Akasaka, Hiroyoshi Yokoi, Takuo Nakagami, Yoshiharu Higuchi, Junichi Yamaguchi, Takumi Kimura, Atsushi Harada, Takeshi Kuroda, Atsushi Takita, Raisuke Iijima, Yoshitaka Murakami, Shigeru Saito. Monotherapy With Prasugrel After Dual-Antiplatelet Therapy for Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk - A Prospective Cohort Study (PENDULUM mono Study).
Circulation journal : official journal of the Japanese Circulation Society.
2020 12; 85(1):27-36. doi:
10.1253/circj.cj-20-0786. [PMID: 33162490] - Amy Sm Lam, Bryan Py Yan, Vivian Wy Lee. Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study.
BMJ open.
2020 12; 10(12):e042229. doi:
10.1136/bmjopen-2020-042229. [PMID: 33273050] - Boris Schnorbus, Andreas Daiber, Kerstin Jurk, Silke Warnke, Jochem Koenig, Karl J Lackner, Thomas Münzel, Tommaso Gori. Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study.
European heart journal.
2020 09; 41(33):3144-3152. doi:
10.1093/eurheartj/ehz917. [PMID: 31899473] - Federica Ilardi, Giuseppe Gargiulo, Roberta Paolillo, Marco Ferrone, Sara Cimino, Giuseppe Giugliano, Gabriele G Schiattarella, Nicola Verde, Eugenio Stabile, Cinzia Perrino, Plinio Cirillo, Enrico Coscioni, Carmine Morisco, Giovanni Esposito. Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome.
Journal of cardiovascular medicine (Hagerstown, Md.).
2020 Sep; 21(9):660-666. doi:
10.2459/jcm.0000000000000981. [PMID: 32520854] - Fernando Scudiero, Guido Parodi. Dual antiplatelet therapy in patients with acute coronary syndrome during the coronavirus disease of 2019 pandemia: the right choice at the right time.
Journal of cardiovascular medicine (Hagerstown, Md.).
2020 08; 21(8):535-537. doi:
10.2459/jcm.0000000000001028. [PMID: 32628420] - Paul C Armstrong, Plinio M Ferreira, Melissa V Chan, Martina H Lundberg Slingsby, Marilena Crescente, Chih-Chin Shih, Nicholas S Kirkby, Adrian J Hobbs, Timothy D Warner. Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti-platelet therapy.
Journal of thrombosis and haemostasis : JTH.
2020 07; 18(7):1705-1713. doi:
10.1111/jth.14826. [PMID: 32278335] - Paul M Haller, Stefan Stojkovic, Edita Piackova, Tijana Andric, Lukas Wisgrill, Andreas Spittler, Johann Wojta, Kurt Huber, Bernhard Jäger. The association of P2Y12 inhibitors with pro-coagulatory extracellular vesicles and microRNAs in stable coronary artery disease.
Platelets.
2020 May; 31(4):497-504. doi:
10.1080/09537104.2019.1648780. [PMID: 31389740] - Hala M F Mohammad, Samy Makary, Hoda Atef, Mohamed El-Sherbiny, Hebatallah H Atteia, Gehan A Ibrahim, Abdelaty Shawky Mohamed, Sawsan A Zaitone. Clopidogrel or prasugrel reduces mortality and lessens cardiovascular damage from acute myocardial infarction in hypercholesterolemic male rats.
Life sciences.
2020 Apr; 247(?):117429. doi:
10.1016/j.lfs.2020.117429. [PMID: 32061670] - Satoshi Shoji, Mitsuaki Sawano, Alexander T Sandhu, Paul A Heidenreich, Yasuyuki Shiraishi, Nobuhiro Ikemura, Koji Ueno, Masahiro Suzuki, Yohei Numasawa, Keiichi Fukuda, Shun Kohsaka. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
JAMA network open.
2020 04; 3(4):e202004. doi:
10.1001/jamanetworkopen.2020.2004. [PMID: 32239221] - William A E Parker, Christian Schulte, Temo Barwari, Fladia Phoenix, Sam M Pearson, Manuel Mayr, Peter J Grant, Robert F Storey, Ramzi A Ajjan. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels.
Cardiovascular diabetology.
2020 01; 19(1):3. doi:
10.1186/s12933-019-0981-3. [PMID: 31910903] - Ovidio De Filippo, Fabrizio D'Ascenzo, Sergio Raposeiras-Roubin, Emad Abu-Assi, Mattia Peyracchia, Pier Paolo Bocchino, Tim Kinnaird, Albert Ariza-Solé, Christoph Liebetrau, Sergio Manzano-Fernández, Giacomo Boccuzzi, Jose Paulo Simao Henriques, Christian Templin, Stephen B Wilton, Pierluigi Omedè, Lazar Velicki, Ioanna Xanthopoulou, Luis Correia, Enrico Cerrato, Andrea Rognoni, Ugo Fabrizio, Iván Nuñez-Gil, Mario Iannaccone, Andrea Montabone, Salma Taha, Toshiharu Fujii, Alessandro Durante, Xiantao Song, Sebastiano Gili, Giulia Magnani, Ferdinando Varbella, Tetsuma Kawaji, Pedro Flores Blanco, Alberto Garay, Giorgio Quadri, Dimitrios Alexopoulos, Berenice Caneiro Queija, Zenon Huczek, Rafael Cobas Paz, José Ramón González Juanatey, María Cespón Fernández, Shao-Ping Nie, Isabel Muñoz Pousa, Masa-Aki Kawashiri, Diego Gallo, Umberto Morbiducci, Federico Conrotto, Antonio Montefusco, Alberto Dominguez-Rodriguez, Angel López-Cuenca, Angel Cequier, Andrés Iñiguez-Romo, Tullio Usmiani, Mauro Rinaldi, Gaetano Maria De Ferrari. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects.
European heart journal. Cardiovascular pharmacotherapy.
2020 01; 6(1):31-42. doi:
10.1093/ehjcvp/pvz048. [PMID: 31511896] - Nishank Jain, Suzanne L Hunt, Huizhong Cui, Milind A Phadnis, Jonathan D Mahnken, Theresa I Shireman, Junqiang Dai, Jawahar L Mehta, Rafia S Rasu. Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis.
Cardiovascular drugs and therapy.
2019 10; 33(5):511-521. doi:
10.1007/s10557-019-06913-w. [PMID: 31729588] - Mitsuhiro Nishihara. Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes.
European journal of drug metabolism and pharmacokinetics.
2019 Oct; 44(5):713-717. doi:
10.1007/s13318-019-00554-y. [PMID: 30993551] - Dietmar Trenk, Laura Hille, Stefan Leggewie, Christian Stratz, Thomas G Nührenberg, Daniel Aradi, Karsten Schrör, Dirk Sibbing. Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options.
Thrombosis and haemostasis.
2019 10; 119(10):1606-1616. doi:
10.1055/s-0039-1693738. [PMID: 31408901] - Bernhard Jäger, Stefan Stojkovic, Paul M Haller, Edith Piackova, Beatrice S Kahl, Tijana Andric, Kris G Vargas, Johann Wojta, Kurt Huber. Course of platelet miRNAs after cessation of P2Y12 antagonists.
European journal of clinical investigation.
2019 Aug; 49(8):e13149. doi:
10.1111/eci.13149. [PMID: 31172515] - Yun Wang, Michael B Nichol, Bryan Py Yan, Joanne Wu, Brian Tomlinson, Vivian Wy Lee. Descriptive analysis of real-world medication use pattern of statins and antiplatelet agents among patients with acute coronary syndrome in Hong Kong and the USA.
BMJ open.
2019 07; 9(7):e024937. doi:
10.1136/bmjopen-2018-024937. [PMID: 31315855] - Michela Faggioni, Usman Baber, Jaya Chandrasekhar, Samantha Sartori, William Weintraub, Sunil V Rao, Birgit Vogel, Bimmer Claessen, Annapoorna Kini, Mark Effron, Zhen Ge, Stuart Keller, Craig Strauss, Clayton Snyder, Catalin Toma, Sandra Weiss, Melissa Aquino, Brian Baker, Anthony Defranco, Sameer Bansilal, Brent Muhlestein, Samir Kapadia, Stuart Pocock, Kanhaiya L Poddar, Timothy D Henry, Roxana Mehran. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
2019 Jul; 94(1):53-60. doi:
10.1002/ccd.28033. [PMID: 30656812] - Carey Kimmelstiel, Ryan Stevenson, Nga Nguyen, Layla Van Doren, Ping Zhang, James Perkins, Navin K Kapur, Andrew Weintraub, Vilma Castaneda, Athan Kuliopulos, Lidija Covic. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.
Thrombosis research.
2019 May; 177(?):59-69. doi:
10.1016/j.thromres.2019.01.017. [PMID: 30851630] - Sergio Raposeiras-Roubín, Emad Abu-Assi, Fabrizio D'Ascenzo, Saleta Fernández-Barbeira, Tim Kinnaird, Albert Ariza-Solé, Sergio Manzano-Fernández, Christian Templin, Lazar Velicki, Ioanna Xanthopoulou, Enrico Cerrato, Giorgio Quadri, Andrea Rognoni, Giacome Boccuzzi, Andrea Montabone, Salma Taha, Alessandro Durante, Sebastiano Gili, Giulia Magnani, Michele Autelli, Alberto Grosso, Pedro Flores Blanco, Alberto Garay, Ferdinando Varbella, Francesco Tommassini, Berenice Caneiro Queija, Rafael Cobas Paz, María Cespón Fernández, Isabel Muñoz Pousa, Diego Gallo, Umberto Morbiducci, Alberto Domínguez-Rodríguez, José Antonio Baz-Alonso, Mariano Valdés, Ángel Cequier, Fiorenzo Gaita, Dimitrios Alexopoulos, Andrés Íñiguez-Romo. Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel.
Revista espanola de cardiologia (English ed.).
2019 Apr; 72(4):298-304. doi:
10.1016/j.rec.2018.05.021. [PMID: 29954720] - Gaurang Nandkishor Vaidya, Abdur Khan, Shahab Ghafghazi. Effect of morphine use on oral P2Y12 platelet inhibitors in acute myocardial infarction: Meta-analysis.
Indian heart journal.
2019 Mar; 71(2):126-135. doi:
10.1016/j.ihj.2019.03.003. [PMID: 31280824] - Monica Verdoia, Patrizia Pergolini, Matteo Nardin, Roberta Rolla, Lucia Barbieri, Paolo Marino, Alessandro Carriero, Harry Suryapranata, Giuseppe De Luca. Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation.
Journal of cardiology.
2019 03; 73(3):198-203. doi:
10.1016/j.jjcc.2018.10.005. [PMID: 30522897] - Mikko T Holmberg, Aleksi Tornio, Maria Paile-Hyvärinen, E Katriina Tarkiainen, Mikko Neuvonen, Pertti J Neuvonen, Janne T Backman, Mikko Niemi. CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel.
Clinical pharmacology and therapeutics.
2019 02; 105(2):448-457. doi:
10.1002/cpt.1177. [PMID: 29998574] - Magdalena Boncler, Joanna Wzorek, Nina Wolska, Dawid Polak, Cezary Watala, Marcin Rozalski. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y12 antagonists.
Vascular pharmacology.
2019 02; 113(?):47-56. doi:
10.1016/j.vph.2018.11.005. [PMID: 30471364] - Maarten A H van Leeuwen, Nina W van der Hoeven, Gladys N Janssens, Henk Everaars, Alexander Nap, Jorrit S Lemkes, Guus A de Waard, Peter M van de Ven, Albert C van Rossum, Tim J F Ten Cate, Jan J Piek, Clemens von Birgelen, Javier Escaned, Marco Valgimigli, Roberto Diletti, Niels P Riksen, Nicolas M van Mieghem, Robin Nijveldt, Niels van Royen. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
Circulation.
2019 01; 139(5):636-646. doi:
10.1161/circulationaha.118.035931. [PMID: 30586720] - Tanya M Laidlaw, Katherine N Cahill, Juan Carlos Cardet, Katherine Murphy, Jing Cui, Brittney Dioneda, Parul Kothari, Benjamin A Raby, Elliot Israel, Joshua A Boyce. A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease.
The Journal of allergy and clinical immunology.
2019 01; 143(1):316-324.e7. doi:
10.1016/j.jaci.2018.06.001. [PMID: 29890239] - Atsushi Kambayashi, Jennifer B Dressman. Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro-In Silico-In Vivo Approach: Case Examples-Dipyridamole, Prasugrel, and Nelfinavir.
Journal of pharmaceutical sciences.
2019 Jan; 108(1):584-591. doi:
10.1016/j.xphs.2018.11.008. [PMID: 30423339] - Yuji Ohno, Hideki Kitahara, Kenichi Fujii, Yukinori Kohno, Noritaka Ariyoshi, Takeshi Nishi, Yoshihide Fujimoto, Yoshio Kobayashi. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis.
Journal of cardiology.
2019 01; 73(1):51-57. doi:
10.1016/j.jjcc.2018.07.001. [PMID: 30055865] - Takanari Kitazono, Yasuo Ikeda, Masakatsu Nishikawa, Satoshi Yoshiba, Kenji Abe, Akira Ogawa. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
Journal of thrombosis and thrombolysis.
2018 Nov; 46(4):488-495. doi:
10.1007/s11239-018-1714-2. [PMID: 30074128] - Niloufar Marsousi, Youssef Daali, Pierre Fontana, Jean-Luc Reny, Virginie Ancrenaz-Sirot, Alexandra Calmy, Serge Rudaz, Jules Alexandre Desmeules, Caroline Flora Samer. Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites.
Clinical pharmacokinetics.
2018 10; 57(10):1347-1354. doi:
10.1007/s40262-018-0637-6. [PMID: 29453687] - Laurent Bonello, Marc Laine, Gilles Lemesle, Etienne Puymirat, Thibaut Dabry, Franck Thuny, Franck Paganelli, Daniel Aradi, Corinne Frere, Stéphane Burtey, Dirk Sibbing, Julien Mancini. Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease.
Thrombosis and haemostasis.
2018 Oct; 118(10):1839-1846. doi:
10.1055/s-0038-1669426. [PMID: 30235475] - Dimitrios Dimitroulis, Milad Golabkesh, David Naguib, Betül Knoop, Lisa Dannenberg, Carolin Helten, Martin Pöhl, Christian Jung, Malte Kelm, Tobias Zeus, Amin Polzin. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Journal of cardiovascular pharmacology.
2018 10; 72(4):186-190. doi:
10.1097/fjc.0000000000000609. [PMID: 29985284] - Matti K Itkonen, Aleksi Tornio, Anne M Filppula, Mikko Neuvonen, Pertti J Neuvonen, Mikko Niemi, Janne T Backman. Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.
Clinical pharmacology and therapeutics.
2018 09; 104(3):495-504. doi:
10.1002/cpt.947. [PMID: 29171020] - Sara Ariotti, Luis Ortega-Paz, Maarten van Leeuwen, Salvatore Brugaletta, Sergio Leonardi, K Martijn Akkerhuis, Stefano F Rimoldi, Gladys Janssens, Umberto Gianni, Jan C van den Berge, Alexios Karagiannis, Stephan Windecker, Marco Valgimigli. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
JACC. Cardiovascular interventions.
2018 08; 11(16):1576-1586. doi:
10.1016/j.jcin.2018.04.022. [PMID: 29805112] - K Korybalska, R Rutkowski, J Luczak, N Czepulis, K Karpinski, J Witowski. The role of purinergic P2Y12 receptor blockers on the angiogenic properties of endothelial cells: an in vitro study.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
2018 Aug; 69(4):. doi:
10.26402/jpp.2018.4.06. [PMID: 30415240] - A Bertling, A C Fender, L Schüngel, M Rumpf, K Mergemeier, G Geißler, W Sibrowski, R Kelsch, J Waltenberger, J A Jakubowski, B E Kehrel. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
Journal of thrombosis and haemostasis : JTH.
2018 06; 16(6):1089-1098. doi:
10.1111/jth.14014. [PMID: 29582544] - Reza Rahmani, Laya Jiriaee, Zahra Jiriaee, Akbar Shafiee, Amir Farhang Zand Parsa. The Incidence of Myocardial Injury after Loading Doses of Clopidogrel versus Prasugrel in the Candidates for Percutaneous Coronary Intervention: A Randomized Controlled Trial.
Critical pathways in cardiology.
2018 06; 17(2):69-72. doi:
10.1097/hpc.0000000000000114. [PMID: 29768313] - Iñigo Lozano, Juan Rondan, Jose M Vegas, Eduardo Segovia. Chronic Kidney Disease and Antiplatelet Therapy: A Worrying Gap Between Evidence Based Medicine and Clinical Practice.
JACC. Cardiovascular interventions.
2018 02; 11(3):319-320. doi:
10.1016/j.jcin.2017.11.016. [PMID: 29413247] - Brian A Moser, Elizabeth S LaBell, Emmanuel Chigutsa, Joseph A Jakubowski, David S Small. Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.
Clinical pharmacokinetics.
2018 02; 57(2):243-254. doi:
10.1007/s40262-017-0556-y. [PMID: 28578536] - María Asunción Esteve-Pastor, Juan Miguel Ruíz-Nodar, Esteban Orenes-Piñero, José Miguel Rivera-Caravaca, Miriam Quintana-Giner, Andrea Véliz-Martínez, Antonio Tello-Montoliu, Vicente PerniasEscrig, Miriam Sandín Rollán, Nuria Vicente-Ibarra, Manuel Jesús MacíasVillanego, Elena Candela Sánchez, Luna Carrillo Alemán, Teresa Lozano, Mariano Valdés, Francisco Marín. Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
Journal of cardiovascular pharmacology and therapeutics.
2018 Jan; 23(1):57-65. doi:
10.1177/1074248417724869. [PMID: 28789568] - Tanja K Rudolph, Alexander Fuchs, Anna Klinke, Andrea Schlichting, Kai Friedrichs, Martin Hellmich, Martin Mollenhauer, Edzard Schwedhelm, Stephan Baldus, Volker Rudolph. Prasugrel as opposed to clopidogrel improves endothelial nitric oxide bioavailability and reduces platelet-leukocyte interaction in patients with unstable angina pectoris: A randomized controlled trial.
International journal of cardiology.
2017 Dec; 248(?):7-13. doi:
10.1016/j.ijcard.2017.06.099. [PMID: 28709700] - Kenzo Uzu, Toshiro Shinke, Hiromasa Otake, Tomofumi Takaya, Tsuyoshi Osue, Masamichi Iwasaki, Hiroto Kinutani, Akihide Konishi, Masaru Kuroda, Hachidai Takahashi, Daisuke Terashita, Ken-Ichi Hirata, Shigeru Saito, Masato Nakamura, Junya Shite, Takashi Akasaka. Morphological and pharmacological determinants of peri-procedural myocardial infarction following elective stent implantation: Optical coherence tomography sub-analysis of the PRASFIT-Elective study.
Journal of cardiology.
2017 Dec; 70(6):545-552. doi:
10.1016/j.jjcc.2017.05.002. [PMID: 28619235] - Marc Laine, Stephane Burtey, Etienne Puymirat, Gilles Lemesle, Laurent Bonello. Research and Therapeutic Nihilisms in Chronic Kidney Disease.
JACC. Cardiovascular interventions.
2017 11; 10(22):2343-2344. doi:
10.1016/j.jcin.2017.08.038. [PMID: 29169505] - Paul Hermant, Damien Bosc, Catherine Piveteau, Ronan Gealageas, BaoVy Lam, Cyril Ronco, Matthieu Roignant, Hasina Tolojanahary, Ludovic Jean, Pierre-Yves Renard, Mohamed Lemdani, Marilyne Bourotte, Adrien Herledan, Corentin Bedart, Alexandre Biela, Florence Leroux, Benoit Deprez, Rebecca Deprez-Poulain. Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox.
Journal of medicinal chemistry.
2017 11; 60(21):9067-9089. doi:
10.1021/acs.jmedchem.7b01444. [PMID: 28985084] - Lisa Schoener, Stefanie Jellinghaus, Bernhardt Richter, Christian Pfluecke, Georg Ende, Marian Christoph, Silvio Quick, Tobias Loehn, Uwe Speiser, David M Poitz, Johannes Mierke, Ruth H Strasser, Karim Ibrahim. Reversal of the platelet inhibitory effect of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor in vitro: a new approach to an old issue.
Clinical research in cardiology : official journal of the German Cardiac Society.
2017 Nov; 106(11):868-874. doi:
10.1007/s00392-017-1128-8. [PMID: 28653184] - Usman Baber, Jaya Chandrasekhar, Samantha Sartori, Melissa Aquino, Annapoorna S Kini, Samir Kapadia, William Weintraub, Joseph B Muhlestein, Birgit Vogel, Michela Faggioni, Serdar Farhan, Sandra Weiss, Craig Strauss, Catalin Toma, Anthony DeFranco, Brian A Baker, Stuart Keller, Mark B Effron, Timothy D Henry, Sunil Rao, Stuart Pocock, George Dangas, Roxana Mehran. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
JACC. Cardiovascular interventions.
2017 10; 10(20):2017-2025. doi:
10.1016/j.jcin.2017.02.047. [PMID: 28780028] - Hitinder S Gurm. P2Y12 Inhibitors in Patients With Chronic Kidney Disease: The Known Unknown.
JACC. Cardiovascular interventions.
2017 10; 10(20):2026-2028. doi:
10.1016/j.jcin.2017.06.028. [PMID: 28780024] - Rishi J Desai, Julia Spoendlin, Helen Mogun, Joshua J Gagne. Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Pharmacotherapy.
2017 Oct; 37(10):1322-1327. doi:
10.1002/phar.2018. [PMID: 28833345] - Christian Schoergenhofer, Eva-Luise Hobl, Thomas Staudinger, Walter S Speidl, Gottfried Heinz, Jolanta Siller-Matula, Christian Zauner, Birgit Reiter, Jacek Kubica, Bernd Jilma. Prasugrel in critically ill patients.
Thrombosis and haemostasis.
2017 08; 117(8):1582-1587. doi:
10.1160/th17-03-0154. [PMID: 28692105] - Tomoko Hasunuma, Hiroyuki Fukase, Atsuhiro Miyazaki, Yasuhiro Nishikawa. Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects.
Clinical drug investigation.
2017 Jul; 37(7):679-685. doi:
10.1007/s40261-017-0525-0. [PMID: 28417436] - Kazuo Umemura, Yasuhiko Ikeda, Nobuko Matsushima, Kazunao Kondo. Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects.
Clinical pharmacology in drug development.
2017 Jul; 6(4):398-407. doi:
10.1002/cpdd.308. [PMID: 27652589] - Aaron E Pritchard, Evelyn L Lockhart. Rumpel-Leede phenomenon in a patient being treated with prasugrel.
Transfusion.
2017 07; 57(7):1642. doi:
10.1111/trf.13962. [PMID: 28675527] - Yue Zhang, János Peti-Peterdi, Anna U Brandes, Anne Riquier-Brison, Noel G Carlson, Christa E Müller, Carolyn M Ecelbarger, Bellamkonda K Kishore. Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice.
Purinergic signalling.
2017 06; 13(2):239-248. doi:
10.1007/s11302-017-9555-6. [PMID: 28233082] - A J Gerrits, J A Jakubowski, A Sugidachi, A D Michelson, A L Frelinger. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Journal of thrombosis and haemostasis : JTH.
2017 05; 15(5):858-867. doi:
10.1111/jth.13627. [PMID: 28092426] - Takeshi Nishi, Noritaka Ariyoshi, Takashi Nakayama, Yoshihide Fujimoto, Kazumasa Sugimoto, Shinichi Wakabayashi, Hideki Hanaoka, Yoshio Kobayashi. Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrel in Japanese patients.
Journal of cardiology.
2017 05; 69(5):752-755. doi:
10.1016/j.jjcc.2016.07.017. [PMID: 27567173] - Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Michela Faggioni, Melissa Aquino, Annapoorna Kini, William Weintraub, Sunil Rao, Samir Kapadia, Sandra Weiss, Craig Strauss, Catalin Toma, Brent Muhlestein, Anthony DeFranco, Mark Effron, Stuart Keller, Brian Baker, Stuart Pocock, Timothy Henry, Roxana Mehran. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
2017 Mar; 89(4):629-637. doi:
10.1002/ccd.26606. [PMID: 27152497] - Eliano P Navarese, Michalina Kolodziejczak, Max-Paul Winter, Arman Alimohammadi, Irene M Lang, Antonino Buffon, Gregory Yh Lip, Jolanta M Siller-Matula. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.
International journal of cardiology.
2017 Jan; 227(?):644-649. doi:
10.1016/j.ijcard.2016.10.084. [PMID: 27810295] - Kazuo Umemura, Takayuki Iwaki. The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers.
Clinical pharmacology in drug development.
2016 Nov; 5(6):480-487. doi:
10.1002/cpdd.259. [PMID: 27514617] - Luca A Ferri, Nuccia Morici, Daniele Grosseto, Giovanni Tortorella, Irene Bossi, Paolo Sganzerla, Michele Cacucci, Girolamo Sibilio, Stefano Tondi, Anna Toso, Maurizio Ferrario, Nicola Gandolfo, Amelia Ravera, Matteo Mariani, Elena Corrada, Leonardo Di Ascenzo, Anna Sonia Petronio, Claudio Cavallini, Nadia Moffa, Stefano De Servi, Stefano Savonitto. A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
American heart journal.
2016 Nov; 181(?):101-106. doi:
10.1016/j.ahj.2016.08.010. [PMID: 27823681] - Kyeong Soo Kim, Jin Cheul Kim, Sung Giu Jin, Dong Wuk Kim, Dong Shik Kim, Chul Soon Yong, Jong Oh Kim, Yu Seok Youn, Kyung Taek Oh, Jong Soo Woo, Han-Gon Choi. Development of novel prasugrel base microsphere-loaded tablet with enhanced stability: Physicochemical characterization and in vivo evaluation in beagle dogs.
Colloids and surfaces. B, Biointerfaces.
2016 Oct; 146(?):754-61. doi:
10.1016/j.colsurfb.2016.07.025. [PMID: 27451362] - Chiara Melloni, Jan H Cornel, Gail Hafley, Megan L Neely, Peter Clemmensen, Dmitry Zamoryakhin, Dorairaj Prabhakaran, Harvey D White, Keith Aa Fox, E Magnus Ohman, Paul W Armstrong, Matthew T Roe. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
European heart journal. Acute cardiovascular care.
2016 Oct; 5(6):443-454. doi:
10.1177/2048872615598631. [PMID: 26228448] - Nishank Jain, Robert F Reilly. Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions.
Seminars in dialysis.
2016 09; 29(5):374-81. doi:
10.1111/sdi.12484. [PMID: 27061079] - Kazuo Umemura, Yasuhiko Ikeda, Kazunao Kondo. Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects.
Drug metabolism and pharmacokinetics.
2016 Aug; 31(4):285-91. doi:
10.1016/j.dmpk.2016.03.006. [PMID: 27474356] - Mark R Thomas, Allison C Morton, Rashed Hossain, Beining Chen, Lei Luo, Nur Nazihah B Md Shahari, Peng Hua, Richard G Beniston, Heather M Judge, Robert F Storey. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction.
Thrombosis and haemostasis.
2016 07; 116(1):96-102. doi:
10.1160/th16-02-0102. [PMID: 27099137] - Pierre Sabouret, Magali Taiel-Sartral, Florence Chartier, Sabine Akiki, Thomas Cuisset. Prasugrel Use in Real Life: A Report From the Outpatient Setting in France.
Clinical cardiology.
2016 Jul; 39(7):378-84. doi:
10.1002/clc.22553. [PMID: 27299993] - Fabiana Rollini, Francesco Franchi, Jenny Hu, Megha Kureti, Niti Aggarwal, Ashwin Durairaj, Yongwhi Park, Michael Seawell, Pedro Cox-Alomar, Martin M Zenni, Luis A Guzman, Siva Suryadevara, Patrick Antoun, Theodore A Bass, Dominick J Angiolillo. Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology.
2016 May; 67(17):1994-2004. doi:
10.1016/j.jacc.2016.02.045. [PMID: 27012781] - Sreekanth Kakarla, Peda Varma Datla, Geetha Kodali, Ganapaty Seru. Analysis of prasugrel active metabolite R-138727 in human plasma: a sensitive, highly selective and fast LC-MS/MS method.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 May; 1020(?):103-10. doi:
10.1016/j.jchromb.2016.03.035. [PMID: 27038402] - Eva-Luise Hobl, Birgit Reiter, Christian Schoergenhofer, Michael Schwameis, Ulla Derhaschnig, Irene Marthe Lang, Thomas Stimpfl, Bernd Jilma. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers.
Clinical research in cardiology : official journal of the German Cardiac Society.
2016 Apr; 105(4):349-55. doi:
10.1007/s00392-015-0927-z. [PMID: 26493304] - Bincy Jose, Peter McCluskey, Niamh Gilmartin, Martin Somers, Dermot Kenny, Antonio J Ricco, Nigel J Kent, Lourdes Basabe-Desmonts. Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs.
Langmuir : the ACS journal of surfaces and colloids.
2016 Mar; 32(11):2820-8. doi:
10.1021/acs.langmuir.5b03540. [PMID: 26910300] - Christian Schoergenhofer, Michael Schwameis, Eva-Luise Hobl, Cihan Ay, Nigel S Key, Ulla Derhaschnig, Bernd Jilma, Alexander O Spiel. Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial.
Clinical science (London, England : 1979).
2016 Mar; 130(6):433-40. doi:
10.1042/cs20150591. [PMID: 26554025] - Victor L Serebruany, Ales Tomek, Alex N Pokov, Moo Hyun Kim. Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?.
Expert review of cardiovascular therapy.
2015 Dec; 13(12):1333-44. doi:
10.1586/14779072.2015.1101343. [PMID: 26513059] - Stephen A O'Connor, Julien Amour, Anne Mercadier, Réjane Martin, Mathieu Kerneis, Jérémie Abtan, Delphine Brugier, Johanne Silvain, Olivier Barthélémy, Pascal Leprince, Gilles Montalescot, Jean-Philippe Collet. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
Circulation. Cardiovascular interventions.
2015 Nov; 8(11):e002786. doi:
10.1161/circinterventions.115.002786. [PMID: 26553698] - Joo Myung Lee, Ji-Hyun Jung, Kyung Woo Park, Eun-Seok Shin, Seok Kyu Oh, Jang-Whan Bae, Jay Young Rhew, Namho Lee, Dong-Bin Kim, Ung Kim, Jung-Kyu Han, Sang Eun Lee, Han-Mo Yang, Hyun-Jae Kang, Bon-Kwon Koo, Sanghyun Kim, Yun Kyeong Cho, Won-Yong Shin, Young-Hyo Lim, Seung-Woon Rha, Seok-Yeon Kim, Sung Yun Lee, Young-Dae Kim, In-Ho Chae, Kwang Soo Cha, Hyo-Soo Kim. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.
Trials.
2015 Sep; 16(?):409. doi:
10.1186/s13063-015-0925-5. [PMID: 26374625] - Mikko T Holmberg, Aleksi Tornio, Hanna Hyvärinen, Mikko Neuvonen, Pertti J Neuvonen, Janne T Backman, Mikko Niemi. Effect of grapefruit juice on the bioactivation of prasugrel.
British journal of clinical pharmacology.
2015 Jul; 80(1):139-45. doi:
10.1111/bcp.12581. [PMID: 25557052] - Gisela Scharbert, Leonore Wetzel, Waltraud C Schrottmaier, Julia B Kral, Thomas Weber, Alice Assinger. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Transfusion.
2015 Jun; 55(6):1320-6. doi:
10.1111/trf.12977. [PMID: 25641006] - Zuzana Motovska, Martina Ondrakova, Frantisek Bednar, Jiri Knot, Jaroslav Ulman, Marek Maly. Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a 'Real World' registry.
Thrombosis research.
2015 Jun; 135(6):1093-9. doi:
10.1016/j.thromres.2015.04.014. [PMID: 25917561] - Tanya M Laidlaw, Joshua A Boyce. Platelets in patients with aspirin-exacerbated respiratory disease.
The Journal of allergy and clinical immunology.
2015 Jun; 135(6):1407-14; quiz 1415. doi:
10.1016/j.jaci.2015.02.005. [PMID: 26051947] - Pierre Deharo, Mathieu Pankert, Jacques Quilici, Guillaume Bonnet, Clemence Bassez, Valentine Verdier, Pierre Morange, Marie-Christine Alessi, Jean-Louis Bonnet, Thomas Cuisset. Chronic kidney disease has a significant impact on platelet inhibition of new P2Y12 inhibitors.
International journal of cardiology.
2015 Apr; 184(?):428-430. doi:
10.1016/j.ijcard.2015.02.077. [PMID: 25755059] - Hae-Sun Jeon, Mi-Jo Kim, Hee-Youn Choi, Yo-Han Kim, Eun-Hwa Kim, A-Reum Kim, Hyun-Jung Park, Kyun-Seop Bae, Hyeong-Seok Lim. Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.
Clinical therapeutics.
2015 Mar; 37(3):563-73. doi:
10.1016/j.clinthera.2015.01.010. [PMID: 25697420] - L R Johnston, A C La Flamme, P D Larsen, S A Harding. Prasugrel inhibits platelet-enhanced pro-inflammatory CD4+ T cell responses in humans.
Atherosclerosis.
2015 Mar; 239(1):283-6. doi:
10.1016/j.atherosclerosis.2015.01.006. [PMID: 25635327] - Susanne Drews, Daniel Bolliger, Christoph Kaiser, Martin Grapow, Oliver Reuthebuch, Friedrich Eckstein, Peter Matt. Prasugrel increases the need for platelet transfusions and surgical reexploration rates compared with clopidogrel in coronary artery bypass surgery.
The Thoracic and cardiovascular surgeon.
2015 Feb; 63(1):28-35. doi:
10.1055/s-0034-1373901. [PMID: 24838516] - Fanny Bonhomme, Robert Bonvini, Jean-Luc Reny, Antoine Poncet, Pierre Fontana. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study.
Platelets.
2015; 26(4):324-30. doi:
10.3109/09537104.2015.1035247. [PMID: 25905916] - Yassine Bouatou, Caroline Flora Samer, Pierre Fontana, Youssef Daali, Jules Desmeules. Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review.
Current drug metabolism.
2015; 16(2):97-104. doi:
10.2174/138920021602150713114437. [PMID: 26179606] - Kousaku Ohno, Hisako Tanaka, Naozumi Samata, Joseph A Jakubowski, Atsuyuki Tomizawa, Makoto Mizuno, Atsuhiro Sugidachi. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
Thrombosis research.
2014 Oct; 134(4):889-94. doi:
10.1016/j.thromres.2014.07.035. [PMID: 25130912] - Douglas Moeckel, Soon Soeg Jeong, Xiaofeng Sun, M Johan Broekman, Annie Nguyen, Joan H F Drosopoulos, Aaron J Marcus, Simon C Robson, Ridong Chen, Dana Abendschein. Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
Science translational medicine.
2014 Aug; 6(248):248ra105. doi:
10.1126/scitranslmed.3009246. [PMID: 25100739] - Miho Kazui, Katsunobu Hagihara, Takashi Izumi, Toshihiko Ikeda, Atsushi Kurihara. Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel.
Drug metabolism and disposition: the biological fate of chemicals.
2014 Jul; 42(7):1138-45. doi:
10.1124/dmd.114.057661. [PMID: 24733788] - J R Glenn, N Dovlatova, A E White, K Dhillon, S Heptinstall, S C Fox. 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Thrombosis and haemostasis.
2014 Mar; 111(3):539-48. doi:
10.1160/th13-07-0581. [PMID: 24258486] - Aline Gabrielli, Yassine Bouatou, Patrick Saudan. [Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
Revue medicale suisse.
2014 Feb; 10(419):487-90, 492. doi:
NULL. [PMID: 24665658] - Kyung-Sang Yu, Kyung Woo Park, Ronan P Kelly, Namyi Gu, Christopher Payne, David S Small, Hyunah C Choi, Eiji Kawakatsu, Philippe Pinton. Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males.
Journal of cardiovascular pharmacology.
2013 Jul; 62(1):72-7. doi:
10.1097/fjc.0b013e318290d9e1. [PMID: 23594968] - Ted Wun, Denis Soulieres, Andrew L Frelinger, Lakshmanan Krishnamurti, Enrico M Novelli, Abdullah Kutlar, Kenneth I Ataga, Charles L Knupp, Lillian E McMahon, John J Strouse, Chunmei Zhou, Lori E Heath, Chuke E Nwachuku, Joseph A Jakubowski, Jeffrey S Riesmeyer, Kenneth J Winters. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
Journal of hematology & oncology.
2013 Feb; 6(?):17. doi:
10.1186/1756-8722-6-17. [PMID: 23414938]